Fabio A Barroso

List of Publications by Year
in descending order

15 papers	1,524 citations	1307594 7 h-index	1058476 14 g-index
15 all docs	15 docs citations	15 times ranked	2044 citing authors

#	Article	IF	Citations
1	Treatment-related fluctuations in Guillain-BarrÃ© syndrome: clinical features and predictors of recurrence. Arquivos De Neuro-Psiquiatria, 2022, , .	0.8	0
2	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
3	Intravenous immunoglobulin treatment for mild Guillain-BarrÃ© syndrome: an international observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1080-1088.	1.9	6
4	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	7.6	190
5	Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 180-188.	3.0	20
6	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	27.0	1,000
7	International Guillainâ€BarrÃ© Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2017, 22, 68-76.	3.1	89
8	The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 107-108.	3.0	6
9	Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 194-204.	3.0	83
10	Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle and Nerve, 2016, 54, 353-360.	2.2	21
11	Recent advances in familial amyloid polyneuropathy. Current Opinion in Neurology, 2015, 28, 494-499.	3.6	5
12	Focal Hypokalemic Paralysis. Journal of Clinical Neuromuscular Disease, 2012, 14, 21-27.	0.7	4
13	Percussion Myotonia. New England Journal of Medicine, 2009, 360, e13.	27.0	2
14	Compound muscle action potential temporal dispersion during hypokalemia. Muscle and Nerve, 2009, 40, 662-663.	2.2	3
15	Hereditary Neuropathy With Liability to Pressure Palsies Manifesting By Recurrent Neuropathic Pain. Journal of Clinical Neuromuscular Disease, 2006, 8, 26-30.	0.7	2